Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Definium Therapeutics, Inc. (DFTX : NSDQ)

• Company Description    Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK. Number of Employees: 106

• Price / Volume Information    Yesterday's Closing Price: $22.50 Daily Weekly Monthly 20 Day Moving Average: 1,552,751 shares Shares Outstanding: 99.70 (millions) Market Capitalization: $2,243.21 (millions) Beta: 2.37 52 Week High: $26.25 52 Week Low: $6.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.27% -7.99% 12 Week 30.13% 20.30% Year To Date 68.04% 55.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE WORLD TRADE CENTER SUITE 8500 - NEW YORK,NY 10007 USA ph: 212-220-6633 fax: - ir@definiumtx.com http://www.definiumtx.com

• General Corporate Information    Officers Robert Barrow - Chief Executive Officer and Director Brandi L. Roberts - Chief Financial Officer Carol Vallone - Director David Gryska - Director Roger Crystal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 24477V105 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/30/26 Share - Related Items Shares Outstanding: 99.70 Most Recent Split Date: 8.00 (0.07:1) Beta: 2.37 Market Capitalization: $2,243.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.04 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -102.86% vs. Previous Quarter: -57.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -100.30 12/31/25 - -82.07 09/30/25 - -86.18 ROA 03/31/26 - -69.22 12/31/25 - -58.73 09/30/25 - -62.29 Current Ratio 03/31/26 - 4.69 12/31/25 - 6.29 09/30/25 - 3.30 Quick Ratio 03/31/26 - 4.69 12/31/25 - 6.29 09/30/25 - 3.30 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 2.80 12/31/25 - 3.36 09/30/25 - 1.70 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.15 12/31/25 - 0.12 09/30/25 - 0.31 Debt-to-Capital 03/31/26 - 12.76 12/31/25 - 10.88 09/30/25 - 23.62

Powered by Zacks Investment Research ©